- The low false-positive and false-negative rates (<1% on repeat determinations of 24-hour sera) have permitted successful screening in selected high-risk populations, as in chemical workers (ref.8) and in the preclinical detection of cancer in 2.3% of medical-surgical cases (ref.4), but the efficacy of screening in larger normal populations has yet to be determined.
- A normal AMA level can occur in non-cancer, in terminal cancer, and in successfully treated cancer in which there is no further evidence of disease; clinical status must be used to distinguish these states.
- As in all clinical laboratory tests, the AMAS®Test is not by itself diagnostic of the presence or absence of disease, and its results can only be assessed as an aid to diagnosis, detection or monitoring of disease in relation to the history, medical signs and symptoms and the overall condition of the patient.
|
|
|
